It seems that by increasing the number of days on which aprepitant is currently administrated in clinical practice (three days), and using higher doses than those used for chemotherapy-induced nausea and vomiting, this non-peptide NK-1 receptor antagonist could be effective in the prevention/treatment of chronic pancreatitis and PC. The gene discussed is TACR1; the disease is chronic pancreatitis.